Search

Giuliana Ribeiro de Carvalho,1,2 Vagner Loduca Lima,2 Glaucia Luciano da Veiga,1 Fernando Adami,3 Beatriz da Costa Aguiar Alves,1 Edimar Cristiano Pereira,4 David Feder,1 Fernando Luiz Affonso Fonseca1,4 1Clinical Analysis Laboratory, Centro Universitário Saúde ABC/Faculdade De Medicina Do ABC, Santo André, Brazil; 2Ophthalmology Discipline, Centro Universitário Saúde ABC-Faculdade de Medicina do ABC, Santo André, Brazil; 3Epidemiology Department, Centro Universitário Saúde ABC/Faculdade De Medicina Do ABC, Santo André, Brazil; 4Pharmaceutical Sciences Department, Universidade Federal De São Paulo, Diadema, BrazilCorrespondence: Fernando Luiz Affonso Fonseca 2000, Lauro Gomes Avenue, Santo Andre CEP: 09060-650, BrazilTel +5511 4993-5488Email profferfonseca@gmail.comIntroduction: Diabetes mellitus (DM) stands out as one of the chronic diseases with the highest morbidity and mortality rates worldwide. Among the many complications of DM, diabetic retinopathy (DR) is one of the causes of blindness in patients aged between 20 and 64 years. At least 90% of the new cases showed to have the retinal structure and function restored when proper treatment was provided.Aim: To evaluate the efficacy of the antiangiogenic bevacizumab in the treatment of DR according not only to the clinical laboratory parameters for glycated hemoglobin (HbA1C) and capillary glycemia but also to the ophthalmological parameters for optical coherence tomography (OCT) and best-corrected visual acuity (BCVA).Patients and Methods: A total of 11 individuals were included and followed up for 12 months after 3 administrations of bevacizumab.Results: Upon associating the ophthalmological and laboratory variables throughout the treatment, no significant alterations could be seen regarding the analyzed variables. However, it was observed that HbA1c values and the total leukocyte count negatively interfered with the treatment response.Conclusion: The current study showed that HbA1c values and the amount of leukocytes negatively interfere with the therapeutic response. Therefore, laboratory analyses of these parameters are recommended for diabetic patients undergoing the above-mentioned treatment.Keywords: diabetic retinopathy, bevacizumab, macular edema